List of contents

Change history

Version	Valid and binding as of:	New minor version	Description, comments (by author)	Author's initials
2.0	**01.10.2015**		**Update**	**Submissions Division**
1.9	**15.11.2014**		**Version published on Swissmedic website**	**Submissions Team**
1.8	**01.11.2013**		**Version published on Swissmedic website**	**Submissions Team**
1.7	**31.07.2013**		**Version published on Swissmedic website**	**Submissions Team**
1.6	**01.07.2013**		**Version published on Swissmedic website**	**Submissions Team**
1.5	**31.03.2013**		**Version published on Swissmedic website**	**Submissions Team**
1.4	**08.05.2012**		**Version published on Swissmedic website**	**Submissions Team**
1.3	**29.11.2010**		**Version published on Swissmedic website**	**SIMES Working Group**
1.2	**22.10.2010**		**Version published on Swissmedic website**	**Superuser eCTD**
1.1	**21.05.2010**		**Version published on Swissmedic website**	**SIMES Working Group**
1.0	**30.10.2009**		**1st valid version, published on Swissmedic website**	**SIMES Working Group**

Authors:	Lead: Ralph Maier, Swissmedic Review team Swissmedic
Responsible:	Submissions Division, Swissmedic
Version / Date:	2.0 / 01.10.2015

Swissmedic • Hallerstrasse 7 • CH-3000 Berne 9 • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

1 Glossary

A brief glossary of terms (for the purpose of this document only) is indicated below:

Term	Definition
Applicant	A pharmaceutical company or its agent submitting information in support of an application.
Applicant's information	Regulatory information submitted by an applicant to receive or to maintain a marketing authorisation that falls within the scope of this guidance document
Application	A collection of documents compiled by a pharmaceutical company or its agent in compliance with Swiss legislation and guidelines in order to seek a marketing authorisation or any amendments thereof. An application may comprise a number of submissions or sequences.
Application Number	The Application Number is assigned to the application by Swissmedic. It tracks the Application at the agency level.
Regulatory Activity	It is used by some review tools to group together several related sequences of an application.
Dossier	Several dosage forms and strengths may be comprised under one product name. Some review tools describe this as a Dossier.
eCTD identifier	An eCTD identifier is a name, code or number used as the directory name in the top-level directory. This can be a proposed trade name, a company internal project code, or the Marketing Authorisation Number.
eCTD Submission or sequence	A single set of information and/or documents supplied by the applicant as a partial or complete, application. In the context of eCTD, this is equivalent to a **sequence**. An eCTD Submission **is an electronic-only submission** in eCTD format supported by paper.
Marketing Authorisation Number	The Marketing Authorisation Number is the unique identifier for the medicinal product and the dosage form for the Swiss market. (Swissmedic Number)
Test eCTD-Submission	A **Test eCTD Submission** is an electronic-only submission by the applicant prior to the official submission.

2 List of Abbreviations

ATC	Anatomical Therapeutical Chemical
CCDS	Company Core Data Sheet
CL	Checklist
CTD	Common Technical Document
DMF	Drug Master File
DTD	Document Type Definition
eCTD	electronic Common Technical Document
EMA	European Medicines Agency
EU	European Union
FO	Form
GMO	Genetically Modified Organisms

Swissmedic • Hallerstrasse 7 • CH-3000 Berne 9 • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

ICH	International Conference on Harmonisation
IfP	Information for Professionals
INN	International Non-proprietary Name
LCM	Life cycle management
LoQ	List of Questions
MAH	Marketing Authorisation Holder
MAN	Marketing Authorisation Number
NeeS	Non-eCTD electronic submission
PDF	Portable Document Format
PI	Product Information
PMF	Plasma Master File
PSUR	Periodic Safety Update Report
RMP	Risk Management Plan (E2E)
Q&A	Questions and Answers document
SIMES	Project “Solution for the Implementation and Management of Electronic Submissions”
SmPC	Summary of Product Characteristics
STF	Study Tagging Files
Swissmedic	Swiss Agency for Therapeutic Products
ToC	Table of Contents
TPA	Therapeutic Product Act (Federal Law on Medicinal Products and Medical Devices) of December 15, 2000 in the past known as LTP (Law on Therapeutic Products) / SR 812.21 Bundesgesetz vom 15. Dezember 2000 über Arzneimittel und Medizinprodukte (Heilmittelgesetz HMG) / SR 812.21 Loi fédérale sur les médicaments et les dispositifs médicaux du 15 décembre 2000 (Loi sur les produits thérapeutiques LPTh)
util	Utility folder in the eCTD Sequence. Contains technical files.
VAM	Ordinance on Medicinal Products of October 17, 2001 / SR 812.212.21(Verordnung über die Arzneimittel) / SR 812.212.21 (Ordonnance sur les médicaments)
XML	Extensible Markup Language

3 Introduction

This questions and answers document is a summary of questions that relate to the Swiss guideline documents (i.e. Module 1 Specification for eCTD, Swiss eCTD validation criteria and Guidance for Industry) and represent Swissmedic’s current view. It is intended to be a dynamic document that supplements and actualizes the above mentioned guideline documents. This questions and answers document will be updated as the guideline documents undergo change control or as new questions are submitted to the agency.

In addition further eCTD Q&A issued by ICH and relating to all regions can be found at http://estri.ich.org/eCTD/index.htm.

4 Questions about the Submission

Question 1-1:
(Q 2-1, V1.9)

How should a collective application be submitted which refers to a paper documented drug product and a drug product in eCTD format?

Swissmedic • Hallerstrasse 7 • CH-3000 Berne 9 • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12

Answer 1-1: *(A 2-1, V1.9):*	The application must be made in eCTD and paper formats according to their previous life cycle. However, Swissmedic recommends the conversion of the paper-based drug product into eCTD before the collective application is submitted.
Question 2-2: *(Q 2-5, V1.9)*	*How should* applications due to stock out situations *be handled?*
Answer 2-2: *(A 2-5, V1.9)*	• Applications due to stock out situations: These refer to market surveillance, require specific documentation and are handled outside of the eCTD. • Temporary marketing authorisations for new products: These can be submitted as eCTD
Question 2-3: *(Q 2-6, V1.9)*	*Which documents should be placed in the section "additional information" addressed in Appendix 1 of the Swiss Module 1 Specification document?*
Answer 2-3: *(A 2-6, V1.9)*	This section should not be used if a document has a defined place within module 1. The section "additional information" can be used for documents which cannot be assigned to the other sections within module 1. New forms should be added to section 1.2.2.99. In case of notifications, a copy of the form Variations Requiring Notification containing the preliminary decision of Swissmedic should be placed here (please refer to question 2-3).

[End of Document]

Swissmedic • Hallerstrasse 7 • CH-3000 Berne 9 • www.swissmedic.ch • Tel. +41 58 462 02 11 • Fax +41 58 462 02 12